An interventional study of Albumin-Platelet Rich Fibrin (Alb-PRF) and Advanced Platelet-Rich Fibrin (A-PRF) in PRF Growth Factor Release, sponsored by Izmir Katip Celebi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Izmir Katip Celebi University · Not applicable, Interventional, and Basic science
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties.
Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release.
This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
Exclusion Criteria:
Blood samples obtained from healthy volunteers were processed using the Albumin-Platelet Rich Fibrin (Alb-PRF) protocol. Growth factor release and resistance to enzymatic degradation were evaluated under standardized laboratory conditions.
Biological: Albumin-Platelet Rich Fibrin (Alb-PRF)
Blood samples obtained from healthy volunteers were processed using the Leukocyte-Platelet Rich Fibrin (L-PRF) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Advanced Platelet-Rich Fibrin+ (A-PRF+).
Biological: Leukocyte-Platelet Rich Fibrin (L-PRF)
Blood samples obtained from healthy volunteers were processed using the Advanced Platelet-Rich Fibrin+ (A-PRF+) protocol. Growth factor release (VEGF, PDGF-BB, and TGF-β1) and resistance to enzymatic degradation were evaluated under standardized laboratory conditions and compared with Albumin-PRF (Alb-PRF) and Leukocyte-Platelet Rich Fibrin (L-PRF) .
Biological: Advanced Platelet-Rich Fibrin (A-PRF)
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
VEGF concentration released from PRF membranes
Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Time frame: Day 1, Day 3, Day 5, and Day 7
PDGF concentration released from PRF membranes
Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Time frame: Day 1, Day 3, Day 5, and Day 7
TGF-B concentration released from PRF membranes
Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA).
Time frame: Day 1, Day 3, Day 5, and Day 7
Resistance to enzymatic degradation
Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations.
Time frame: 60 minutes and 120 minutes
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Izmir Katip Celebi University